Anthony H V Schapira
Schapira, Anthony H. V. (Anthony Henry Vernon)
Schapira, Anthony Henry Vernon
Schapira, Anthony H. V.
Schapira, A.H.V.
Schapira, Tony
Schapira, A. H. V. (Anthony Henry Vernon)
VIAF ID: 76600059 (Personal)
Permalink: http://viaf.org/viaf/76600059
Preferred Forms
- 100 0 _ ‡a Anthony H V Schapira
- 200 _ | ‡a Schapira ‡b Anthony H. V.
- 100 1 _ ‡a Schapira, A. H. V. ‡q (Anthony Henry Vernon)
-
-
-
-
-
-
-
- 100 1 _ ‡a Schapira, Anthony H. V. ‡q (Anthony Henry Vernon)
-
-
- 100 1 _ ‡a Schapira, Anthony Henry Vernon
- 100 1 _ ‡a Schapira, Anthony Henry Vernon
-
- 100 1 _ ‡a Schapira, Anthony Henry Vernon
-
4xx's: Alternate Name Forms (12)
Works
Title | Sources |
---|---|
Blue books of practical neurology | |
Czas rozpoczęcia leczenia w chorobie Parkinsona : czy potrzebna jest ponowna ocena? | |
Med. reg., 1993: | |
Mitochondria : DNA, proteins and disease | |
Mitochondrial disorders in neurology, 1994: | |
Mitochondrial function and dysfunction | |
Movement disorders four | |
Muerte neuronal y enfermedad de Parkinson : origen y terapéutica | |
Muscle diseases, c1999: | |
Neurodegeneration | |
Neurology and clinical neuroscience | |
Obecne i przyszłe leczenie farmakologiczne choroby Parkinsona | |
Parkinsonian disorders in clinical practice | |
Parkinson's disease | |
Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors. | |
Pozaruchowe objawy choroby Parkinsona : rozpoznanie i postępowanie | |
Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces. | |
Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms | |
Pramipexole protects against MPTP toxicity in non-human primates | |
Progress in European neurology 2012-2013. | |
Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. | |
Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors | |
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells | |
Recent advances in neurology 2013-2014 | |
Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. | |
Relapsing neuropathy in an 18-year-old woman | |
Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency. | |
Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication | |
Restless legs syndrome: an update on treatment options | |
Retinal thinning in Gaucher disease patients and carriers: results of a pilot study | |
RLS patients: who are they? | |
Role of oxidative damage in Friedreich's ataxia | |
Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). | |
Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency | |
Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids | |
Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells | |
Sirkka-Liisa Leinonen. | |
Somatic copy number variant mutations in alpha-synuclein and genome-wide in brains of synucleinopathy cases | |
Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity | |
Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice | |
Systemic PTEN-Akt1-mTOR pathway activity in patients with normal tension glaucoma and ocular hypertension: A case series. | |
Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant | |
Update of the Human MitBASE database. | |
α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection | |
자가포식 모니터링을 위한 분석법의 사용 및 해석에 대한 지침(4판) |